Unraveling genetic risk factors for Alzheimer's disease
Study suggests promoting conversion of glucose into brain energy could reduce risk or delay disease onset in risk gene carriers
- Date:
- July 2, 2018
- Source:
- Society for Neuroscience
- Summary:
- The strongest genetic risk factor for Alzheimer's disease may impair the brain's ability to convert its primary fuel source into usable energy, finds a study of female mice. The research suggests therapeutic strategies that promote brain energy conversion in risk gene carriers could help to reduce risk or delay onset of the disease.
- Share:
The strongest genetic risk factor for Alzheimer's disease may impair the brain's ability to convert its primary fuel source into usable energy, finds a study of female mice published in JNeurosci. The research suggests therapeutic strategies that promote brain energy conversion in risk gene carriers could help to reduce risk or delay onset of the disease.
Approximately 20 percent of people produce a version of human apolipoprotein E called ApoE4, which increases their risk of developing Alzheimer's disease, while the five percent of people who produce the rare ApoE2 appear to show some protection against Alzheimer's.
Liqin Zhao and colleagues explored the influence of these ApoE variations -- in addition to the most common ApoE3 that does not confer risk for or protection against Alzheimer's disease -- on the chemical reactions that transform glucose and ketone bodies into the form of energy used by cells.
The brains expressing the three types of proteins handled the process differently, which may underlie their distinct effects on Alzheimer's risk and protection. While the ApoE4 brains struggled to use glucose, they appeared to utilize ketone bodies -- the brain's secondary fuel source -- to compensate for the energy deficiency.
Story Source:
Materials provided by Society for Neuroscience. Note: Content may be edited for style and length.
Journal Reference:
- Long Wu, Xin Zhang, Liqin Zhao. Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention. The Journal of Neuroscience, 2018; 2262-17 DOI: 10.1523/JNEUROSCI.2262-17.2018
Cite This Page: